Clara Biotech hits $850K in seed funding roundup, preparing to launch first product
June 15, 2021 | Startland News Staff
An emerging biotech startup in the region is reporting a busy spring with a significant seed round already raised and key steps under way to launch its product: a solution that removes manufacturing roadblocks for breakthrough drugs.
“We’re in an exciting and growing space and currently have low regulatory hurdles in the research stage,” said Jim West, co-founder of Clara Biotech, a Lawrence-based company already buoyed by its founding team’s expertise in exosome technologies, pharmaceutical development, engineering and building life science companies.
Elevator pitch: Clara Biotech is building an exosome isolation platform that solves a huge roadblock around manufacturing that helps the entire biopharma industry make future breakthrough drugs that may not otherwise get approved. We founded Clara Biotech to help move exosomes from research to patient.
Jim West, Clara Biotech
“We’re looking for smart money investors who can help us develop our market position, scale the technology and become the platform that companies can use to get exosome therapies to the patients who need them most,” he continued, detailing Clara Biotech’s momentum in a company snapshot update.
Off the heels of announcing an undisclosed investment by Kansas City-based Fountain Innovation Fund, the startup has raised $850,000 for its seed round, West said, with additional investments from angel investors in Boston, San Francisco, India and Kansas City.
Dr. Mei He, Clara Biotech
Clara Biotech recently received a tranche of angel tax credits, still available to qualified investors, he added.
The seed round is expected to help the company debut its beta ExoRelease exosome isolation kit, as well as continue to scale, West said.
Click here to read Clara Biotech’s full snapshot update.
“We are generating revenue and launching our first product,” he said. “At a recent conference for exosome therapeutics, sample preparation quality was the major limiting factor in manufacturing and receiving FDA approval. Our groundbreaking solution resulted in a 70 percent lead conversion rate of all companies attending (which includes investment groups and competitors). We’re currently working with and growing a number of paying early customers including some major pharmaceutical players.”
Founded in 2018 at the Bioscience and Technology Business Center in Lawrence, Clara Biotech’s therapeutic applications range from personalized medicine, targeted drug delivery, immunotherapy, and orphan and rare diseases. It’s solutions are focused on early cancer detection, Alzheimer’s disease, and virus detection.
Click here to learn more about Clara Biotech and how its technology works.
This story is possible thanks to support from the Ewing Marion Kauffman Foundation, a private, nonpartisan foundation that seeks to build inclusive prosperity through a prepared workforce and entrepreneur-focused economic development. The Foundation works to change conditions, address root causes, and break down systemic barriers so that all people – regardless of race, gender, or geography – have the opportunity to achieve economic stability, mobility, and prosperity.
For more information, visit www.kauffman.org and connect with us at www.twitter.com/kauffmanfdn and www.facebook.com/kauffmanfdn.
2021 Startups to Watch
stats here
Related Posts on Startland News
PrairieFood grows power of its micro-carbon ag solution with a pipeline of human connection
Startland News’ Startup Road Trip series explores innovative and uncommon ideas finding success in rural America and Midwestern startup hubs outside the Kansas City metro. LAWRENCE — Entrepreneurship is all about networking, Robert Herrington said. “You never know where a pivot or direction is going to come from,” said Herrington, an early member of the Pipeline…
C2FO marks $300B in funding for businesses as entrepreneurs navigate ongoing credit crunch
Rapid marketplace expansion in the first half of 2023 helped push Leawood-based C2FO — the world’s on-demand working capital platform — past the $300-billion mark in total funding to its customers. This record funding amount reflects invoices paid an average of 31 days early via C2FO’s platform. C2FO gets vital, low-cost capital into customers’ hands…
Froyo with a ’tini twist: Entrepreneur collaboration serves alcoholic frozen yogurt in KC
Kansas City is excited by the new flavor combinations popping up as two entrepreneurs give customers a taste of collaboration, said Isaac Collins, teasing a line of alcoholic frozen yogurt that’s already hitting cups in the metro. Through a partnership with KC-based Brain Freeze Mobile Daiquiri, Collins’ Yogurtini locations have begun a series of happy…
How Meshuggah Bagels ‘built a bakery without a recipe’ — now expanding to Liberty, Lawrence
Pete Linde tested 72 bagel recipes before hitting perfection with number 73, said Janna Linde. She knows because she tried every single test bagel. “Pete worked on that recipe for about a year. He had a notebook and took notes on every little tweak and modification he made. I’d see the big hand mixer come…